{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Act promotes the designation of significant drug combinations that include 2 or more drugs offering potential advancement in treating serious diseases. The Act encourages the codevelopment of drug combinations that include at least 2 unapproved drugs to advance treatment for serious diseases. The codevelopment task force under the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012 can review requests from drug manufacturers to determine if a combination of 2 or more drugs is significant. The Secretary must respond within 30 days and review if the combination meets the requirements. The Secretary will designate a combination of drugs as significant if it meets the requirements, providing notice to the requester. The Secretary will designate a combination of drugs as significant if it meets the requirements, providing notice to the requester. A request for designation must be made concurrently with, or after, submission of an application. The Secretary will develop and publish an initial list of significant drug combinations within 180 days of the enactment of the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. The Secretary will update the list of significant drug combinations annually, adding new combinations and removing ones that no longer meet the requirements. This process is in accordance with the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. The Secretary annually updates the list of significant drug combinations, extending market exclusivity by 6 months for drugs in approved combinations. The Secretary annually updates the list of significant drug combinations, extending market exclusivity by 6 months for drugs in approved combinations. Limitations apply to the approval of supplements or subsequent applications for drugs in designated significant combinations. The Secretary annually updates the list of significant drug combinations, extending market exclusivity by 6 months for drugs in approved combinations. Limitations apply to the approval of supplements or subsequent applications for drugs in designated significant combinations. If a drug in a significant drug combination is submitted for review, the Secretary must take action within 6 months. The Secretary updates the list of significant drug combinations annually, granting 6 months of market exclusivity for approved combinations. Limitations apply to supplements or subsequent applications for drugs in designated significant combinations. If a drug in a significant combination is submitted for review, the Secretary must act within 6 months. The definition of 'significantly advance treatment' for drug combinations is provided in the section. The amendment allows for the evaluation of drug combinations in active controlled trials to assess serious morbidity endpoints. Additionally, it includes provisions for fast-tracking products intended for serious or life-threatening conditions or designated as significant drug combinations. The amendment allows for the evaluation of drug combinations in active controlled trials to assess serious morbidity endpoints and fast-track products for serious or life-threatening conditions. Additionally, a Codevelopment Task Force is established. The Secretary of Health and Human Services will establish an interagency task force within 6 months of the Act's enactment to promote the codevelopment of drugs in significant combinations. The task force will include experts in research and drug development for serious diseases like cancer, and will be responsible for recommending a list of significant drug combinations for designation by the Secretary. The task force will develop a list of significant drug combinations for designation by the Secretary under the Federal Food, Drug, and Cosmetic Act. The list will be made publicly available for comments, and revised based on feedback before submission to the Secretary and Congress. The task force will annually update and submit a list of significant drug combinations to the Secretary and Congress, after making updates publicly available for comment. Additionally, the task force will submit a policy report identifying challenges to codevelopment of drugs in combinations. The task force will submit a report with recommendations to the Secretary and Congress on policy changes to support the codevelopment of drugs in significant combinations. Before submitting the report, a draft will be made publicly available for comments from the public. The task force will submit a report with recommendations on policy changes to support the codevelopment of significant drug combinations. FACA does not apply to the task force's duration. A significant drug combination involves 2 or more drugs that advance treatment for serious diseases. The task force will submit a report with recommendations on policy changes to support the codevelopment of significant drug combinations involving at least 2 unapproved drugs. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on significant drug combinations. Interim findings will be shared with a task force and the public for comments. Final findings will be submitted to Congress within 5 years."
}